Recent Updates
Recently added Catalysts
STRO Positive Sentiment

Bill Newell, CEO Interviewed by Brad Loncar, Founder, Biotech TV – “Sutro Biopharma’s CEO on ADCs, non-cell protein synthesis, and more”

Key Takeaway: In a recent interview, Bill Newell, CEO of Sutro Biopharma, discussed the company's latest collaboration with Ipsen and its focus on developing therapies in the folate receptor alpha space. He emphasized the importance of non-cell protein synthesis in their innovative approach. The interview was conducted by Bard Loncar, founder of Biotech TV.
Price reaction · baseline $50.9 (2024-04-03 close) · hit pre-market · clean, no other STRO news in the window
day 0 close · peak
-3.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Sutro Biopharma's CEO discusses promising partnerships.
  • Focus on innovative therapies using non-cell protein synthesis.
  • Recent deal with Ipsen highlights strategic growth.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~13 mo
Low dilution risk
Lead asset
STRO-004
Phase 1 · Head and Neck Squamous Cell Carcinoma HNSCC

Full Press Release Details

[et_pb_section fb_built=”1″ _builder_version=”4.16″ custom_padding=”0px||||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_post_title author=”off” categories=”off” comments=”off” admin_label=”Bill Newell, CEO Interviewed by Brad Loncar, Founder, Biotech TV – %22Sutro Biopharma’s CEO on ADCs, non-cell protein synthesis, and more%22″ _builder_version=”4.23.4″ title_level=”h2″ title_text_color=”#0c71c3″ title_font_size=”28px” title_letter_spacing=”1px” title_line_height=”1.4em” meta_text_color=”#000000″ hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_post_title][et_pb_divider color=”#0badbc” divider_weight=”2px” _builder_version=”4.16″ global_colors_info=”{}”][/et_pb_divider][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.17.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_button button_url=”https://www.biotechtv.com/post/sutro-biopharma-april-4-2024″ url_new_window=”on” button_text=”View Interview” button_alignment=”left” admin_label=”View Interview – Button” _builder_version=”4.23.4″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#0C71C3″ button_bg_color=”#FFFFFF” button_border_width=”1px” button_border_color=”#0C71C3″ button_border_radius=”3px” button_icon=”A||divi||400″ button_icon_color=”#0C71C3″ button_on_hover=”off” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_button][et_pb_text _builder_version=”4.23.4″ _module_preset=”default” text_text_color=”#000000″ text_font_size=”19px” text_letter_spacing=”1px” text_line_height=”1.8em” hover_enabled=”0″ sticky_enabled=”0″]
Bill Newell describes this week’s deal with Ipsen, the folate receptor alpha space, designing therapies with non-cell protein synthesis, and Sutro’s numerous partnerships
Speakers:
• Bill Newell, CEO, Sutro Biopharma
• Bard Loncar, Founder, Biotech TV
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

Frequently Asked Questions

What did Bill Newell discuss in the interview?

He discussed Sutro's deal with Ipsen and their focus on non-cell protein synthesis.

Who conducted the interview with Bill Newell?

The interview was conducted by Bard Loncar, founder of Biotech TV.

What is Sutro Biopharma's focus area?

Sutro Biopharma focuses on therapies in the folate receptor alpha space.

What is the significance of the Ipsen deal?

The Ipsen deal highlights Sutro's strategic growth and partnership opportunities.

Last updated: Apr 4, 2024